Incidental findings
An Incidental Prostate Finding — on PET-CT
If your PET-CT scan, done for a different cancer, has flagged uptake in the prostate, this is not a diagnosis. FDG — the tracer used in most PET scans — is poorly suited to prostate tissue, which makes the finding genuinely ambiguous. Your treating team will decide what to look at next.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed September 2026
- Not a diagnosis — Incidental uptake in the prostate on an FDG-PET scan cannot confirm or rule out prostate cancer on its own.
- FDG is a poor fit for prostate — Many prostate tumours absorb very little glucose, making FDG an unreliable marker for this organ.
- Several causes are possible — Benign prostatic enlargement, prostatitis and normal variation can all produce uptake on FDG-PET.
- A clear next step exists — PSA testing and a urology referral give your team the information to decide whether further investigation is needed.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
If your PET-CT has shown uptake in the prostate, this does not confirm prostate cancer. FDG — the standard tracer — is poorly suited to prostate tissue, so incidental uptake can reflect several conditions. Your oncologist will determine the next investigation, which typically begins with a PSA blood test and a urology review.
CION offers PET-CT in Hyderabad from Rs 10,499 — among the lowest published prices in the city, with no hidden charges. Indicative price, as of September 2026.
What do the terms in your PET-CT report mean?
- Incidental finding
- Something seen on the scan that was not the reason the scan was ordered. It does not mean it is serious — it means it was not expected and needs to be assessed separately.
- FDG (fluorodeoxyglucose)
- The radioactive tracer injected before most PET scans. Cells that use a lot of glucose absorb more of it and appear brighter. Prostate tissue often does not follow this pattern, which is why FDG is a poor tool for assessing the prostate.
- Uptake
- The amount of FDG a tissue absorbs. In the prostate, uptake can be caused by benign enlargement, inflammation or normal metabolic activity — not only by cancer.
- SUV (standardised uptake value)
- The number in your report describing how much tracer the area absorbed. In the prostate the SUV alone is not reliable enough to distinguish cancer from a benign cause, and your team will not act on it in isolation.
- PSMA-PET
- A different PET scan using a tracer that binds specifically to prostate tissue rather than tracking glucose. It is far more accurate for the prostate than FDG-PET, and is the scan your team is most likely to consider if dedicated prostate imaging is needed.
- PSA (prostate-specific antigen)
- A protein produced by the prostate gland, measured in a blood test. An elevated or rising PSA level is one of the first things your team will check after an incidental prostate finding on PET-CT.
What should you do before your next appointment?
- Bring the full PET-CT report and the imaging disc — not just the summary letter your referring doctor received.
- Tell your oncologist which cancer the original scan was performed for, so the incidental finding can be put in context.
- Ask whether a PSA blood test has been ordered. If not, ask whether it should be.
- Note any urinary symptoms — difficulty starting, frequent urination, blood in urine — and mention them at your appointment.
- Tell your team about every medication, supplement and traditional remedy you are currently taking.
- Ask whether a urology referral is the next step, and if so, how soon it can be arranged.
PET-CT Partner Centres
PET-CT Scan Centres in Hyderabad
CION offers PET-CT scans through 4 trusted partner PET-CT centres across Hyderabad, so you can choose the one closest to you. Call 18002028726 and we’ll guide you to the earliest available appointment.
PET-CT Centre — Punjagutta
PET-CT Centre — Himayatnagar
PET-CT Centre — Narayanaguda
These are partner diagnostic centres within the CION network. Toll-free booking: 18002028726.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What do patients ask most about this finding?
Why is FDG-PET unreliable for prostate cancer?
Most cancers grow rapidly and consume large amounts of glucose. FDG-PET works well for them because the glucose-hungry tissue absorbs the tracer and shows up brightly. Prostate cancer, particularly in early and intermediate forms, tends to grow slowly and use relatively little glucose. This means many prostate tumours produce little or no FDG signal. The same scan that reliably stages a lung cancer can miss a prostate cancer entirely, and can make benign prostate activity appear suspicious. ASCO and ESMO guidance does not recommend FDG-PET for prostate cancer staging for exactly this reason.
Does uptake in my prostate mean I have prostate cancer?
It cannot confirm that, and it cannot rule it out. Benign prostatic hyperplasia — the non-cancerous enlargement that affects many men as they age — commonly causes FDG uptake. Prostatitis, an inflammation of the prostate, does too. Normal variation in metabolic activity is another cause. Your report has identified a finding that requires a dedicated assessment, not a diagnosis that has been made. The purpose of the next steps is to establish what the finding actually represents.
What is PSMA-PET and why might my team suggest it?
PSMA stands for prostate-specific membrane antigen — a protein found in high concentrations on the surface of prostate cancer cells. A PSMA-PET scan uses a tracer that binds to this protein rather than tracking glucose. This makes it far more specific to prostate tissue than FDG-PET. ASCO and ESMO recognise PSMA-PET as significantly more accurate for detecting and staging prostate cancer than FDG-based imaging. If the investigation finds a reason to look more closely at the prostate, PSMA-PET is the dedicated scan your team is most likely to consider.
Will this investigation interrupt my current cancer treatment?
For most patients, a PSA blood test and a urology referral can happen alongside ongoing treatment for the primary cancer without disruption. Whether anything beyond that affects your schedule depends on what the investigation finds. Your oncologist and urologist will make that decision together, with your primary treatment priorities in view. Do not stop or delay your current treatment because of this finding without speaking to your team first.
Could this finding have been there for years without being noticed?
Yes. A PET-CT ordered for a different cancer is not a prostate-specific scan, and incidental findings of this kind are often seen on scans done for an entirely separate reason. The fact that it appears now does not mean it developed recently — it may have been present and simply never looked for before. This is part of what makes the finding ambiguous, and why the appropriate response is a structured assessment rather than any immediate conclusion.
Did you know?
ASCO and ESMO guidance does not list FDG-PET as a recommended staging tool for prostate cancer, because most prostate tumours absorb too little glucose to produce a reliable signal.
This is precisely why an incidental prostate uptake finding on an FDG scan is genuinely ambiguous — and why the next investigation uses a different approach entirely.
Source: ASCO and ESMO Prostate Cancer Guidelines
Book a PET-CT at CION from Rs 10,499 — among the lowest published prices in Hyderabad — with an oncologist-reviewed report and a free Rs 950 consultation, across 4 partner centres. Indicative price, as of September 2026.
Explore 94 more Understanding Your PET-CT Report topics
Incidental Findings
- A Second Unrelated Cancer Found on PET-CT
- An Incidental Bone Finding on PET-CT
- An Incidental Breast Finding on PET-CT
- An Incidental Kidney or Adrenal Finding
- An Incidental Liver Lesion on PET-CT
- An Incidental Lung Nodule Found on PET-CT
- An Incidental Prostate Finding on PET-CT
- An Incidental Thyroid Nodule on Your PET Scan
- Do All Incidental Findings Need Investigation?
- Focal Bowel Uptake: Could It Be a Polyp?
- Incidental Findings on a PET-CT Scan: What They Are
- Incidental Heart Findings on a Cancer PET Scan
- The Cost of Chasing an Incidental Finding
- What to Ask Your Doctor About an Incidental Finding
False Positives, False Negatives & Pitfalls
- Bladder, Kidney and Ureter Activity on PET
- Bone Marrow Uptake After Growth Factor Injections
- Bowel Uptake: Normal, Inflammation or Something Else?
- Brown Fat Uptake: A Common Cause of Confusing Findings
- Does a Suspicious PET Finding Always Need a Biopsy?
- Getting a Second Read of Your PET-CT Images
- How Often Is a PET-CT Scan Wrong?
- Muscle Uptake After Exercise or Injections
- Thymic and Rebound Uptake in Younger Patients
- Uptake After Radiotherapy: Inflammation or Disease?
- Uptake at a Biopsy or Surgery Site
- What Causes a False Negative on a PET Scan?
- What Causes a False Positive on a PET Scan?
- What Happens If Two Scans Disagree?
- Which Cancers Do Not Show Well on PET-CT?
- Why the Brain Always Lights Up on PET
Infection, TB & Inflammation on PET
- Can Tuberculosis Look Like Cancer on a PET Scan?
- Dental Infection and Jaw Uptake on PET
- Fungal Infection and Abscess on PET-CT
- How Long Should You Wait After an Infection Before a PET Scan?
- If It Might Be Infection, What Test Comes Next?
- Inflammation After Injections, Vaccines and Cannulas
- Old Healed TB and Calcified Nodes on PET-CT
- PET-CT for Fever of Unknown Origin
- PET-CT for Suspected Infection in Implants and Prostheses
- PET-CT for Vasculitis and Inflammatory Conditions
- Pneumonia and Recent Chest Infection on PET
- Sarcoidosis on PET-CT: The Great Mimic
- TB or Cancer? How Doctors Tell Them Apart
- Thyroid Uptake on PET: Diffuse vs Focal
Reading Your Report: Core Terms
- 'Cannot Be Excluded' and Other Cautious Phrases
- 'Deauville Score' on a Lymphoma PET Report
- 'FDG Avid': What It Means on Your Report
- 'Hypermetabolic': What the Word Actually Means
- 'Hypometabolic' and 'Photopenic' Findings
- 'Impression' vs 'Findings': Which Section Should You Read?
- 'Interval Change' and 'Stable Since Previous Study'
- 'Krenning Score' on a DOTANOC or DOTATATE Report
- 'Lymphadenopathy' on Your PET Report
- 'Metabolically Active Disease': What It Tells You
- 'Metastasis' and 'Distant Spread' on Your Report
- 'Mildly FDG Avid' vs 'Intensely FDG Avid'
- 'No Abnormal FDG Uptake': Is That a Clear Scan?
- 'Physiological Uptake': Normal Areas That Always Light Up
- 'Residual Disease' vs 'Complete Metabolic Response'
- 'Sub-Centimetre Node' and Why Size Matters on PET
- 'Suspicious for Malignancy': How Certain Is That?
- How Long Does a PET-CT Report Take?
- How to Read Your PET-CT Report: A Section-by-Section Guide
- Should You Read Your Own PET-CT Report Before the Consult?
- TNM Staging on a PET-CT Report
- Why Your Report Mentions the Liver and Blood Pool
Response Assessment Scores & Criteria
- Complete Metabolic Response: What It Means
- Deauville Score 1 to 5: The Lymphoma Scale Explained
- End-of-Treatment PET Scan: What It Decides
- How Doctors Judge Whether Treatment Is Working on PET-CT
- Interim PET Scan During Chemotherapy: Why It Is Done
- Metabolic Response vs Size Response: Why They Differ
- PERCIST Criteria: How Metabolic Response Is Measured
- Partial Metabolic Response: Is That Good Enough?
- Progressive Metabolic Disease: What Happens Next
- RECIST vs PERCIST: Size vs Activity
- Stable Metabolic Disease: Good News or Bad?
- Tumour Flare and Pseudoprogression on PET
- What Is a Deauville 3 and Why Is It Ambiguous?
- Why the Scan Says One Thing and You Feel Another
SUV Values Explained
- Comparing SUV Between Two Scans: Is It Meaningful?
- Does a Higher SUV Mean a More Aggressive Cancer?
- Factors That Change Your SUV Reading
- High SUV but Not Cancer: When the Number Misleads
- Is My SUVmax of 4 High? Reading Your Specific Number
- Low SUV but Still Cancer: The PET-Negative Cancers
- SUV in Non-Cancer Conditions
- SUVmax, SUVmean and SUVpeak: What Is the Difference?
- What Is SUV on a PET Scan?
- What Is a Normal SUV Value?
- What SUV Value Indicates Cancer?
- Why Blood Sugar Changes Your SUV Result
- Why Did My SUV Go Down but Not to Zero?
- Why Did My SUV Go Up After Treatment?
Your next step
Talk to an oncologist about your scan
Your PET-CT report read by a senior oncologist, explained in plain language, with a free 45-minute consultation.
Common questions
Frequently asked questions
Why does my PET-CT report mention the prostate if the scan was for a different cancer?
A PET-CT covers the whole body, and radiologists report everything they see — not just what the scan was ordered for. Noting an unexpected finding is the radiologist doing their job correctly. It means the area needs a dedicated assessment, not that the finding is necessarily serious, and not that it was being looked for. Your oncologist will review it alongside your primary cancer care.
Should I be worried about how high the uptake number looks on my report?
The SUV number in your report is not a reliable guide to whether the finding is benign or malignant. In the prostate, elevated uptake can occur with benign enlargement, inflammation or normal variation. Your team will not make a clinical decision based on that number alone. A high or low SUV in the prostate leads to the same response: a PSA test and a urology review to understand what the finding actually represents.
What tests are done next?
The first step is usually a PSA blood test. If PSA is elevated or the clinical picture warrants it, further investigation may include a multiparametric MRI of the prostate, a PSMA-PET scan, or — if those results indicate it is necessary — a tissue biopsy. The sequence and urgency depend on your full clinical picture. Your oncologist and urologist will decide together which steps to take and in what order.
Can this be investigated without a biopsy?
Often, yes — at least in the early stages. PSA testing, an MRI and a PSMA-PET scan can together give your team a much clearer picture of whether the finding is significant before any tissue sampling is considered. A biopsy is arranged only when those results suggest it is necessary. Many incidental prostate findings on FDG-PET turn out not to require one.
How long will it take to find out if this is serious?
A PSA blood test gives results within days. If MRI or PSMA-PET is needed, the timeline depends on scheduling and how urgently your team categorises the finding, but most initial assessments complete within a few weeks. If the wait is affecting you, raise it directly with your oncologist — asking for a clear expected date is a reasonable and practical thing to do.
I was already being treated for one cancer — does this mean I now have two?
Not necessarily, and it would be wrong to assume that before the investigation is complete. An incidental prostate finding on FDG-PET is a starting point for assessment, not a second diagnosis. A proportion of such findings are benign. Your team will run a structured investigation alongside your primary care, keeping the two coordinated. If the uncertainty is affecting you, tell your team — that is part of what they are there for.